eligibility_summary
Inclusion: adults ≥18 with advanced solid tumors post‑SOC/none, measurable disease, ECOG 0–1, ≥12‑wk life expectancy, adequate organ function, tumor tissue/biopsy, WOCBP contraception. Exclusion: prior TOP1‑ADC, active brain mets, >G1 toxicities, recent systemic therapy/RT/surgery, serious lung, liver (incl transplant) or pancreatic disease, major cardiac disease, recent TE/CVA, uncontrolled infection (controlled HIV/HBV/HCV allowed), allergy, other trials, pregnancy, recent other cancers (exceptions), severe comorbidity, chest RT <1 yr, GI obstruction, live vaccine ≤30 d, strong CYP3A4/1A2 use, symptomatic ascites.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06234423 tests CUSP06, a cadherin‑6 (CDH6)–directed antibody‑drug conjugate (ADC). Mechanism: a monoclonal antibody binds CDH6 on tumor cell surfaces, is internalized, and releases a cytotoxic payload intracellularly to kill cancer cells (payload type not specified here). Target cells/pathways: CDH6‑expressing tumor cells, particularly in platinum‑refractory/resistant ovarian cancer and other advanced solid tumors, CDH6 is a cell‑adhesion molecule (cadherin) on epithelial tumor cells, and ADC engagement exploits CDH6 surface expression to deliver targeted cytotoxicity, leading to DNA damage and apoptosis in CDH6‑positive cells.